Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged Coherus Biosciences
Coherus denied institution on Enbrel® IPRs – how does that affect Sandoz?

The PTAB has denied institution of two IPRs filed by Coherus Biosciences against patents covering Enbrel®’s proteins, the ‘182 and ‘522 patents.  The IPRs were not filed by Sandoz, but they will most likely affect Sandoz.  Sandoz already has FDA approval to market Erelzi®, which is its biosimilar for Enbrel®.  And Sandoz is going to trial against Amgen in April.  How do Coherus IPR decisions affect Sandoz's decision to launch at risk?  Or to settle with Amgen?

Read More
Markman AdvisorsAmgen, Sandoz, Novartis, Enbrel, Erelzi, biologics, biologic, biosimilar, Coherus Biosciences, FDA, patent, Inter Partes Review, IPR, 182 patent, 522 patent, protein, PTAB, Federal Circuit, Cuozzo Comment
Sandoz lost two IPRs challenging Humira® patents - what does this mean for other biosimilars?

Sandoz was denied institution on two IPRs against Humira® patents owned by AbbVie.  As we previously discussed, in late 2017, Sandoz filed eight different IPRs against Humira® patents.  Two of those IPRs just failed to reach institution.  What are the take-aways, for Sandoz and any other Humira® biosimilars?

Read More
Markman AdvisorsAbbVie, Humira, Sandoz, Amgen, Coherus Biosciences, Coherus, IPR, Inter Partes Review, PTAB, patent, formulation, psoriasis Comment